Ichnos Glenmark Submits IND for Trispecific ISB 2301
Ichnos Glenmark files IND for ISB 2301, a trispecific biologic targeting three tumor antigens with dual T cell and NK cell engagement.


The IND submission for ISB 2301 places Ichnos Glenmark at the leading edge of a CMC challenge that few biologics manufacturers have navigated: demonstrating process control, characterization, and sterility assurance for a molecule engineered to engage three distinct tumor-associated antigens while simultaneously recruiting both T cells and natural killer (NK) cells. For QA directors and regulatory affairs leads, the filing signals that the agency will be evaluating a CMC package of unusual structural complexity under 21 CFR Part 312.
Multispecific biologics of this architecture require manufacturing platforms capable of producing and purifying constructs with multiple binding domains without compromising molecular integrity or introducing immunogenic impurities. Process validation strategies that work for conventional monoclonal antibodies do not translate directly; comparability protocols, reference standard qualification, and release assay development each carry additional layers of scientific justification. The IND stage is where FDA reviewers will scrutinize whether the proposed manufacturing process can deliver consistent product quality attributes batch to batch.
Ichnos Glenmark has not disclosed the contract or in-house manufacturing arrangement supporting the program, but the scalability question is material. Trispecific formats typically demand tighter control over cell culture conditions and downstream purification steps than bispecifics, and any deviation in glycosylation or domain folding can affect both potency and safety. Plant heads overseeing biologics suites should note that the agency's expectations around ICH Q10 pharmaceutical quality systems apply with equal force to novel modalities, and that first-in-class programs often generate precedent-setting CMC review correspondence.
The oncology indication positions ISB 2301 in a competitive landscape where several multispecific programs are advancing through early-phase trials, but the trispecific mechanism, targeting three tumor-associated antigens with dual immune-cell engagement, remains a relatively uncharted regulatory path. FDA's Division of Oncology Products will assess not only the preclinical safety package but also whether the proposed Phase I dose-escalation design adequately accounts for the cytokine release risk profile associated with simultaneous T cell and NK cell activation.
The first clinical dose, pending FDA clearance of the IND, will mark the earliest human data point for this mechanism and will set the analytical and manufacturing benchmarks that the program carries into subsequent phases.
Source: Media4Growth via Indian Pharma Post, 18 November 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.



Discussion